-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Corporate News] Recently, AbSci, an AI pharmaceutical company that has been on the market for only one year, announced layoff.
The announcement shows that the main reason is that macroeconomic conditions have forced the company to make business adjustment.
According to media reports, the proportion of layoffs is about 20.
It is worth mentioning that its CEO Sean McClain also made it clear that he would cut off unnecessary business and focus on the business that can create the greatest value in the futur.
It is understood that Absci is an AI protein design company, mainly through AI technology and synthetic biology for biopharmaceutical development, protein printing and bacterial engineerin.
On July 22, 2021, Absci was listed on Nasdaq in the United State.
The issue price on that day was US$16, and the closing price rose 394% from the issue price, with a market value of nearly US$2 billio.
Following the IPO, the stock price has been on the rise, reaching nearly $3 billion in August 2021.In January 2022, Absci reached a cooperation agreement with Merck, with a total transaction value of US$610 millio.
In fact, in recent years, with the increasingly fierce competition in drug innovation, more and more hopes have been placed on AI pharmaceuticals, which are expected to help the research and development of new drugs, shorten the research and development cycle, improve the success rate of research and development, and reduce the cost of research and developmen.
It began to continue to be hot and was favored by capita.
At present, in addition to the continuous emergence of a large number of AI pharmaceutical companies, a large number of domestic and foreign leading pharmaceutical companies such as Novartis, Pfizer, GSK, AstraZeneca, Sanofi, and Eli Lilly have also tested the water layout of AI research and development of new drugs, and continue to use AI in A.
The pharmaceutical track is sieging the cit.
Among them, Lilly is one of the main representative.
As early as November 7, 2020, during the 3rd China International Import Expo, Lilly China, Beijing Changjiang Pharmaceutical Development Foundation and Shanghai Yingtong Medical Technology C.
, Lt.
chose to join hands to officially launch the artificial intelligence simulation of psoriasi.
and management project.
In December 2021, Shanghai Qilu Ruige Pharmaceutical Research and Development C.
, Lt.
reached a cooperation with Eli Lill.
The two parties will cooperate closely in preclinical drug development, clinical research and commercialization in the next few years to jointly develop drugs for metabolic disease.
Innovative therap.
It can be said that where there are difficulties in the development of new drugs, there will be AI pharmaceutical.
Therefore, driven by many multinational pharmaceutical companies, the entire domestic AI pharmaceutical track has never been tepid to a big outbrea.
According to the research report of CITIC Securities, in 2020, the investment and financing in the domestic AI pharmaceutical field will exceed 1 billion yuan, an increase of nearly 7 times year-on-yea.
In 2021, AI pharmaceuticals will still be favore.
According to incomplete statistics, a total of 34 financing events occurred in the domestic AI pharmaceutical field this year, involving a total financing amount of about 4 billion yua.
Entering 2022, financing events in the field of AI pharmaceuticals continue to be stage.
However, it should be noted that the industry believes that AI pharmaceuticals can come to the stage, and it is more of a boom generated by capita.
Judging from the current AI pharmaceutical companies starting to lay off employees, the AI pharmaceutical boom is gradually dissipating, and challenges have continued to com.
It is reported that in addition to the announcement of layoffs by AbSci, in July, the first molecule DSP-1181 designed by AI to enter the clinic has also been "abandoned" by pharmaceutical companies because it did not meet expectation.
In general, AI pharma offers only one possibility to increase the probability of succes.
As for whether it is real and feasible, a series of studies such as follow-up animal experiments and clinical trials are needed to verif.
Therefore, from the clinic to the market, the probability of drug development failure is no less than the drug discovery proces.
In this context, the industry expects that a large number of AI pharmaceutical companies will embark on the road of "throttling" if they fail to achieve the "open source" effect in the short ter.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
The announcement shows that the main reason is that macroeconomic conditions have forced the company to make business adjustment.
According to media reports, the proportion of layoffs is about 20.
It is worth mentioning that its CEO Sean McClain also made it clear that he would cut off unnecessary business and focus on the business that can create the greatest value in the futur.
It is understood that Absci is an AI protein design company, mainly through AI technology and synthetic biology for biopharmaceutical development, protein printing and bacterial engineerin.
On July 22, 2021, Absci was listed on Nasdaq in the United State.
The issue price on that day was US$16, and the closing price rose 394% from the issue price, with a market value of nearly US$2 billio.
Following the IPO, the stock price has been on the rise, reaching nearly $3 billion in August 2021.In January 2022, Absci reached a cooperation agreement with Merck, with a total transaction value of US$610 millio.
In fact, in recent years, with the increasingly fierce competition in drug innovation, more and more hopes have been placed on AI pharmaceuticals, which are expected to help the research and development of new drugs, shorten the research and development cycle, improve the success rate of research and development, and reduce the cost of research and developmen.
It began to continue to be hot and was favored by capita.
At present, in addition to the continuous emergence of a large number of AI pharmaceutical companies, a large number of domestic and foreign leading pharmaceutical companies such as Novartis, Pfizer, GSK, AstraZeneca, Sanofi, and Eli Lilly have also tested the water layout of AI research and development of new drugs, and continue to use AI in A.
The pharmaceutical track is sieging the cit.
Among them, Lilly is one of the main representative.
As early as November 7, 2020, during the 3rd China International Import Expo, Lilly China, Beijing Changjiang Pharmaceutical Development Foundation and Shanghai Yingtong Medical Technology C.
, Lt.
chose to join hands to officially launch the artificial intelligence simulation of psoriasi.
and management project.
In December 2021, Shanghai Qilu Ruige Pharmaceutical Research and Development C.
, Lt.
reached a cooperation with Eli Lill.
The two parties will cooperate closely in preclinical drug development, clinical research and commercialization in the next few years to jointly develop drugs for metabolic disease.
Innovative therap.
It can be said that where there are difficulties in the development of new drugs, there will be AI pharmaceutical.
Therefore, driven by many multinational pharmaceutical companies, the entire domestic AI pharmaceutical track has never been tepid to a big outbrea.
According to the research report of CITIC Securities, in 2020, the investment and financing in the domestic AI pharmaceutical field will exceed 1 billion yuan, an increase of nearly 7 times year-on-yea.
In 2021, AI pharmaceuticals will still be favore.
According to incomplete statistics, a total of 34 financing events occurred in the domestic AI pharmaceutical field this year, involving a total financing amount of about 4 billion yua.
Entering 2022, financing events in the field of AI pharmaceuticals continue to be stage.
However, it should be noted that the industry believes that AI pharmaceuticals can come to the stage, and it is more of a boom generated by capita.
Judging from the current AI pharmaceutical companies starting to lay off employees, the AI pharmaceutical boom is gradually dissipating, and challenges have continued to com.
It is reported that in addition to the announcement of layoffs by AbSci, in July, the first molecule DSP-1181 designed by AI to enter the clinic has also been "abandoned" by pharmaceutical companies because it did not meet expectation.
In general, AI pharma offers only one possibility to increase the probability of succes.
As for whether it is real and feasible, a series of studies such as follow-up animal experiments and clinical trials are needed to verif.
Therefore, from the clinic to the market, the probability of drug development failure is no less than the drug discovery proces.
In this context, the industry expects that a large number of AI pharmaceutical companies will embark on the road of "throttling" if they fail to achieve the "open source" effect in the short ter.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
